BHLBIO

"Better human life"

bHLBIO develops the innovative drug for the healthy human life, using our novel CUPID platform which can monitor in real time the Protein-Protein Interaction (PPI) in living cell.

bHLBIO is a private biotech company located in Ochang (R&D) and Seoul (Admin), Korea.
At BHLBIO, we are developing an innovative chemical- or peptide-drug (mainly anti-cancer drug) using
our unique Cell-based Un-/identified Protein Interaction Discovery (CUPID) platform. CUPID system can monitor,
in real time, the intracellular protein-protein interactions (PPIs) that are considered as undruggable targets.
(For technical information, please refer the paper; “Direct Monitoring of the Inhibition of Protein-Protein Interactions
in Cells by Translocation of PKCd Fusion Proteins”, Angew. Chem. Int. Ed. 2011, 50, 1314 -1317).
Using CUPID platform, we are developing KRAS:BRAF interaction inhibitor as an anti-cancer drug, and it is under lead optimization stage.
In addition, drug discovery pipeline, we are actively providing CRO service using our CUPID platform,
and as a result, recently we successfully completed Donga-ST's requested PPI project.